BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 25010179)

  • 21. [Vismodegib in metastasized basal cell carcinoma].
    Reinders MG; Dirix L; Mosterd K; van Doorn R
    Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversible cutaneous side effects of vismodegib treatment.
    Kwong B; Danial C; Liu A; Chun KA; Chang AL
    Cutis; 2017 Mar; 99(3):E19-E20. PubMed ID: 28398426
    [No Abstract]   [Full Text] [Related]  

  • 23. Vismodegib in basal cell carcinoma.
    Amaria RN; Bowles DW; Lewis KD; Jimeno A
    Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Four-year experience with vismodegib hedgehog inhibitor therapy.
    Simone PD; Schwarz JM; Strasswimmer JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1264-5. PubMed ID: 27185433
    [No Abstract]   [Full Text] [Related]  

  • 25. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
    Kwon GP; Ally MS; Bailey-Healy I; Oro AE; Kim J; Chang AL; Aasi S; Tang JY
    J Am Acad Dermatol; 2016 Jul; 75(1):213-5. PubMed ID: 27317518
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.
    Soura E; Plaka M; Dessinioti C; Chasapi V; Stefanaki C; Antoniou C; Stratigos A
    Pediatr Dermatol; 2018 Nov; 35(6):e334-e336. PubMed ID: 30178564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
    Mathis J; Doerr T; Lin E; Ibrahim SF
    Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral hedgehog-pathway inhibitors for basal-cell carcinoma.
    Lear JT
    N Engl J Med; 2012 Jun; 366(23):2225-6. PubMed ID: 22670909
    [No Abstract]   [Full Text] [Related]  

  • 30. Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.
    Calzavara Pinton P; Licitra L; Peris K; Santoro A; Ascierto PA
    Future Oncol; 2015; 11(9):1429-35. PubMed ID: 25952787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib.
    Lucero OM; Fitzmaurice S; Thompson C; Leitenberge J
    Dermatol Online J; 2018 Feb; 24(2):. PubMed ID: 29630158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A massive neglected giant basal cell carcinoma in a schizophrenic patient treated successfully with vismodegib.
    Andersen RM; Lei U
    J Dermatolog Treat; 2015; 26(6):575-6. PubMed ID: 25909367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabis for Vismodegib-Related Muscle Cramps in a Patient With Advanced Basal Cell Carcinoma.
    Kutiel TS; Vornicova O; Bar-Sela G
    J Pain Symptom Manage; 2018 May; 55(5):e1-e2. PubMed ID: 29454899
    [No Abstract]   [Full Text] [Related]  

  • 34. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.
    Brinkhuizen T; Reinders MG; van Geel M; Hendriksen AJ; Paulussen AD; Winnepenninckx VJ; Keymeulen KB; Soetekouw PM; van Steensel MA; Mosterd K
    J Am Acad Dermatol; 2014 Nov; 71(5):1005-8. PubMed ID: 25199678
    [No Abstract]   [Full Text] [Related]  

  • 36. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib.
    Iarrobino A; Messina JL; Kudchadkar R; Sondak VK
    J Am Acad Dermatol; 2013 Jul; 69(1):e33-4. PubMed ID: 23768306
    [No Abstract]   [Full Text] [Related]  

  • 37. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma.
    Orouji A; Goerdt S; Utikal J; Leverkus M
    Br J Dermatol; 2014 Aug; 171(2):431-3. PubMed ID: 24446722
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of locally advanced basal cell carcinoma with vismodegib.
    Moreiras Arias N; Vázquez Veiga H; Sánchez-Aguilar D
    Med Clin (Barc); 2023 May; 160(9):413-414. PubMed ID: 36646552
    [No Abstract]   [Full Text] [Related]  

  • 39. Metastatic basal cell carcinoma: complete remission under vismodegib.
    Wruhs M; Muin D; Stella A; Steiner A; Feldmann R
    J Dtsch Dermatol Ges; 2021 Sep; 19(9):1353-1354. PubMed ID: 34390169
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment of advanced basal cell carcinoma with vismodegib followed by radiotherapy].
    Janela-Lapert R; Dubray B; Duval-Modeste A; Castel M
    Ann Dermatol Venereol; 2020 Nov; 147(11):780-782. PubMed ID: 32505377
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.